Establishment Labs Holdings Inc. (ESTA) is an Industrial Specialties company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for ESTA, including 3 SEC filings, 2 earnings updates and 1 analyst rating. The most recent was published Nov 6, 2026.
ESTA rankings
Financial highlights
Full financials- Revenue, TTM
- $264.03M
- Revenue growth
- +38.3%
- Net income, TTM
- -$38.45M
- Net margin
- -14.6%
- Free cash flow, TTM
- -$21.60M
- Cash
- $75.81M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks48-56%
2026-05-172026-11-08
Mix1690d
- Insider6(38%)
- Other3(19%)
- SEC Filings3(19%)
- Analyst2(13%)
- Earnings2(13%)
Activity · 52 weeks9955 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Establishment Labs Holdings Inc.10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- SECSEC Form 8-K filed by Establishment Labs Holdings Inc.8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs® Reports Third Quarter 2026 Financial ResultsRevenue Increases 33.9% to $72.0 Million, Driven by 119% U.S. Growth Achieves First Quarter of Positive Operating and Free Cash Flow and Raises Full-Year Revenue Guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2026. Third Quarter Business Highlights Announced a new supply agreement with NuSil to support long-term manufacturing capacity and future growth. Received FDA approval for additional smaller Motiva implant sizes, expanding the range of options availa
- PREstablishment Labs® to Announce Third Quarter 2026 Financial Results on October 29Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2026, before the market opens on Thursday, October 29, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results.To participate in the conference call, Dial: (+1) 877-407-8037 (US & Canada) / (+1) 201-689-8037 (International). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com.About Establishment
- ANALYSTStifel initiated coverage on Establishment Labs with a new price targetStifel initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $85.00
- SECSEC Form 8-K filed by Establishment Labs Holdings Inc.8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States. The approval adds 28 new sizes to the Motiva U.S. portfolio, including implants as small as 105 cc, and expands the combinations of base, projection and volume available across Mini, Demi and Full profiles in both the Motiva SmoothSilk Round and Ergonomix product lines. The expanded portfolio includes the foll
- INSIDERDirector Gillin Leslie was granted 262 shares, increasing direct ownership by 1% to 18,856 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Schutter Edward J was granted 253 shares, increasing direct ownership by 0.14% to 178,205 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Lewin Nicholas Sheridan was granted 389 shares, increasing direct ownership by 0.04% to 1,080,349 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Slotkin Bryan was granted 253 shares, increasing direct ownership by 0.77% to 33,052 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Custin Ann was granted 301 shares, increasing direct ownership by 1% to 24,626 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- PREstablishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic ImplantsEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements took place during the 11th World Symposium on Ergonomic Implants (WSEI), in Istanbul, Turkey. WSEI brought together over 1,000 plastic surgeons from 57 countries and featured 127 individual scientific presentations and educati
- INSIDERChief Executive Officer Caldini Filippo covered exercise/tax liability with 682 shares, decreasing direct ownership by 1% to 48,829 units (SEC Form 4) (tax liability)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- ANALYSTEstablishment Labs upgraded by Citigroup with a new price targetCitigroup upgraded Establishment Labs from Neutral to Buy and set a new price target of $92.00
- PRThe GLP-1 Boom Created a Tissue Gap Fillers Were Not Built ForRENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs themselves were never designed to address. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to address. On August 3, 2026, Conexeu Sciences Inc. (NASDAQ:CNXU) President and Chief Executive Officer Miles Harrison sat down with IPO Edge for a fireside chat that put that
- SECSEC Form 10-Q filed by Establishment Labs Holdings Inc.10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- SECEstablishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs® Reports Second Quarter 2026 Financial ResultsEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Highlights and Outlook (Unaudited) Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 $24.7 million of sales in the United States, up 26% from Q1 2026 Guidance raised to $269 million to $271 million, an increase from previous guidance of $266.5 million to $268.5 million Minimally invasive revenue of $12.1 million for the quarter Gross margin of 70.6% compa
- SECSEC Form SCHEDULE 13G filed by Establishment Labs Holdings Inc.SCHEDULE 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
- PREstablishment Labs® to Announce Second Quarter 2026 Financial Results on August 6Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results. To participate in the conference call, Dial: (+1) 888-396-8049 (US & Canada) / (+1) 416-764-8646 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com About Establishment L
- INSIDERDirector Chacon Quiros Juan Jose was granted 11,315 shares, increasing direct ownership by 25% to 56,508 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERSEC Form 4 filed by Director Lewin Nicholas Sheridan4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERAmendment: Director Harris Taylor C. was granted 3,722 shares (SEC Form 4)4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Gillin Leslie was granted 196 shares, increasing direct ownership by 1% to 18,594 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
ESTA FAQ
11 questionsWhat does Establishment Labs Holdings Inc. do?
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through...What is the latest news on ESTA?
In the last 30 days Quantisnow tracked 6 wire items for ESTA: 3 SEC filings, 2 earnings updates and 1 analyst rating. The most recent was published on November 6, 2026.What is ESTA revenue?
Establishment Labs Holdings Inc. (ESTA) reported $264.03M of revenue for the twelve months ended Sep 30, 2026. That is up 38.3% from the year before. Revenue for fiscal 2025 was $211.08M.Is ESTA profitable?
No. Establishment Labs Holdings Inc. reported a net loss of $38.45M for the twelve months ended Sep 30, 2026.How much cash and debt does ESTA have?
Establishment Labs Holdings Inc. reported $75.81M in cash and cash equivalents and $267.82M of debt on its most recent balance sheet in SEC filings.Where does ESTA stock trade?
Establishment Labs Holdings Inc. (ESTA) is listed on NASDAQ.What sector and industry is ESTA in?
Establishment Labs Holdings Inc. operates in the Health Care sector, Industrial Specialties industry.When did Establishment Labs Holdings Inc. go public?
Establishment Labs Holdings Inc. (ESTA) completed its IPO in 2018.What are analysts saying about ESTA?
Across the last 8 analyst actions on Establishment Labs Holdings Inc., there were 2 upgrades and 1 downgrade. The most recent action was from Stifel: Buy with a $85.00 price target on 2026-10-15. Recent price targets range from $48.00 to $92.00.What companies are similar to ESTA?
Notable peers in the same industry include ALGN (Align Technology Inc.), ZBH (Zimmer Biomet Holdings Inc.), STE (STERIS plc (Ireland)), EW (Edwards Lifesciences Corporation), ISRG (Intuitive Surgical Inc.). Compare ESTA side-by-side with any of them on Quantisnow.How can I track ESTA on Quantisnow?
Quantisnow aggregates Establishment Labs Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESTA to receive live email and push alerts on every new disclosure.